Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Consumer Use Behavior Study to Measure the Puffing Topography of Heated Tobacco Products

29. juni 2026 oppdatert av: RAI Services Company

A Consumer Use Behavior Study to Measure the Puffing Topography of Heated Tobacco Products (Glo and Glo Plus)

This is a parallel design cohort consumer use study to measure the puffing topography of two HTP devices, with two variants of HTP consumables ("sticks"), collectively referred to as the study investigational products (Study IP), among a sample of 240 primary users of combustible cigarettes in the United Kingdom (UK). Participants will be using the products for five days at home. Participants demographic characteristics (including age and biological sex), and tobacco- and nicotine-containing products (TNPs) use history will be collected using self-reported questionnaires. Participants will be asked to complete daily surveys using a survey link. Surveys will collect data on the number of CC smoked and number of sticks consumed the previous day in addition to any other tobacco or nicotine product used. In addition, at the end of the study, participants will complete a survey regarding overall product liking and purchase intent.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

200

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Cheshunt, Storbritannia
        • Cheshunt Community Sports Park
      • Sheffield, Storbritannia
        • Channing Hall

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • Ability to read, understand, and be willing to sign an ICF and complete questionnaires written in English.
  • Generally healthy male or female, between age 21-65 years (inclusive at the time of consent), verified with government-issued identification.
  • All female (assigned at birth) candidate participants and those who identify as "intersex" or "unknown" during screening who agree to take the pregnancy test on site and receive a negative result, and who affirm at the SEV that they are not pregnant or intending to become pregnant.
  • Self-report currently smoking at least five CPD on smoking days in the past 30 days.
  • Smoke CC on at least 27 days out of last 30 days.
  • Have smoked at least 100 factory-made filtered CC in their lifetime prior to SEV.
  • Indicate a willingness to use an HTP.
  • Agree to participate in the study and to abide by the study restrictions and requirements, including the use of the assigned Study IP, as described in the ICF.
  • Agree not to allow any other person to use any product provided to them for use during this study.

Exclusion Criteria:

  • Female participants who self-report they are pregnant or breastfeeding or could become pregnant or start breastfeeding in the next 6 months from the study start date.
  • Women who self-report they are not intending to use adequate contraception methods to prevent pregnancy.

    a) Examples of acceptable contraception methods are, but not limited to: i. Surgical sterilization (hysterectomy, bilateral tubal ligation/occlusion, bilateral oophorectomy, bilateral salpingectomy); ii. Established use of oral, implantable, injectable, or transdermal methods of contraception associated with inhibition of ovulation; iii. Physical barrier method (e.g., condom, diaphragm/sponge/cervical cap) with spermicide; iv. Non-hormone releasing intrauterine devices (IUD) or hormone-releasing IUDs (e.g., Mirena or Kyleena); v. Vasectomized partner; vi. Abstinence from heterosexual intercourse (as a lifestyle choice, not just for the purpose of study participation); and vii. Post-menopausal who are not on hormone replacement therapy.

  • Males who self-report they are not willing to use a barrier method of contraception (e.g., a condom with spermicide) or to refrain from donating sperm from the time of signing the informed consent until the EOS, unless they have undergone a vasectomy or were abstinent from heterosexual intercourse, or their female partner was not able to bear children.
  • Individuals who self-report having pacemakers or other embedded electronic medical devices.
  • Individuals who self-report having an unstable heart condition, severe hypertension or diabetes.
  • Individuals who self-report they are sensitive to nicotine.
  • Individuals who respond with 'Poor' or 'Don't know' to general physical or mental health.
  • Individuals who have used a nicotine replacement therapy (NRT) product or a prescription drug to help stop smoking (e.g., varenicline, bupropion) in the past 30 days.
  • Individuals who are employed by a company that manufactures tobacco, HTPs, marketing or in ongoing litigation with a tobacco company.
  • Individuals who self-report that they are planning to quit all nicotine products in the next three months.
  • Individuals who are personally, have household members, or have close family or friends in ongoing or past litigation with a company that manufactures tobacco or HTPs.
  • People who have taken part in a tobacco/nicotine research study in the past 30 days.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: HTP Device 1
Tobacco Flavor
Menthol Flavor
Eksperimentell: HTP Device 2
Tobacco Flavor
Menthol Flavor

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To measure the puffing topography of primary CC smokers when using either the glo or glo plus device with one of two stick variants during a five-day use period.
Tidsramme: 5 days

The primary endpoints of this study will be measured in using built-in topography measures and the product use behavior (PUB) instrument (Study Arm 1 only). The data will include:

  • Mean number of puffs per day
  • Mean estimated puff volume (Study Arm 1) only)
  • Mean puff duration
  • Mean duration between puffs taken (inter-puff-interval; IPI)
  • Number of stick consumption episodes per day (as defined in the statistical analysis plan [SAP]
5 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Determine the frequency of use of the glo and glo plus devices in Standard and Boost Mode
Tidsramme: 5 days
This secondary endpoint will be measured using the built-in topography measures through the Product Use Behavior (PUB) device
5 days
Determine the frequency of use of the glo plus pen detached from the charger pack (Study Arm 2 only)
Tidsramme: 5 days
This secondary endpoint will be measured using the built-in topography measures through the Product Use Behavior (PUB) device
5 days
Determine the average daily consumption (ADC) of CC smoked, sticks consumed, and other TNPs used
Tidsramme: 5 days
Through self-reported questionnaires
5 days
Determine overall product liking and purchase intent
Tidsramme: 5 days
Overall Product Liking: 1 (Strongly Dislike) - 10 (Strongly Like) Purchase Intent: 1 (Definitely would not purchase) - 10 (Definitely would purchase)
5 days
Characterize demographic characteristics
Tidsramme: 5 days
5 days
Determine the safety profile (i.e., adverse events/experiences [AEs]) of the Study IP
Tidsramme: 5 days
5 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Studieleder: Melissa Tapia, Ph.D., RAIS Company

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. juni 2026

Primær fullføring (Antatt)

1. juli 2026

Studiet fullført (Antatt)

1. juli 2026

Datoer for studieregistrering

Først innsendt

5. juni 2026

Først innsendt som oppfylte QC-kriteriene

29. juni 2026

Først lagt ut (Faktiske)

30. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

30. juni 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. juni 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • PHI252503

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .